230 related articles for article (PubMed ID: 26799497)
1. Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines.
Hertz DL; Caram MV; Kidwell KM; Thibert JN; Gersch C; Seewald NJ; Smerage J; Rubenfire M; Henry NL; Cooney KA; Leja M; Griggs JJ; Rae JM
Pharmacogenomics; 2016 Feb; 17(3):231-40. PubMed ID: 26799497
[TBL] [Abstract][Full Text] [Related]
2. Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma.
Reichwagen A; Ziepert M; Kreuz M; Gödtel-Armbrust U; Rixecker T; Poeschel V; Reza Toliat M; Nürnberg P; Tzvetkov M; Deng S; Trümper L; Hasenfuss G; Pfreundschuh M; Wojnowski L
Pharmacogenomics; 2015; 16(4):361-72. PubMed ID: 25823784
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for anthracycline-associated cardiotoxicity.
Reinbolt RE; Patel R; Pan X; Timmers CD; Pilarski R; Shapiro CL; Lustberg MB
Support Care Cancer; 2016 May; 24(5):2173-2180. PubMed ID: 26563179
[TBL] [Abstract][Full Text] [Related]
4. Association of genetic polymorphisms NCF4 rs1883112, CBR3 rs1056892, and ABCC1 rs3743527 with the cardiotoxic effects of doxorubicin in children with acute lymphoblastic leukemia.
Gándara-Mireles JA; Lares-Asseff I; Reyes Espinoza EA; Blanco JG; González Font AE; Córdova Hurtado LP; Castañeda VL; Fierro IV; Romero LP; Reyes HA
Pharmacogenet Genomics; 2021 Jul; 31(5):108-115. PubMed ID: 34096893
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.
Visscher H; Ross CJ; Rassekh SR; Barhdadi A; Dubé MP; Al-Saloos H; Sandor GS; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Brown AM; Rogers PC; Phillips MS; Rieder MJ; Carleton BC; Hayden MR;
J Clin Oncol; 2012 May; 30(13):1422-8. PubMed ID: 21900104
[TBL] [Abstract][Full Text] [Related]
6. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.
Aminkeng F; Ross CJ; Rassekh SR; Hwang S; Rieder MJ; Bhavsar AP; Smith A; Sanatani S; Gelmon KA; Bernstein D; Hayden MR; Amstutz U; Carleton BC;
Br J Clin Pharmacol; 2016 Sep; 82(3):683-95. PubMed ID: 27197003
[TBL] [Abstract][Full Text] [Related]
7. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.
Visscher H; Ross CJ; Rassekh SR; Sandor GS; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Rogers PC; Rieder MJ; Carleton BC; Hayden MR;
Pediatr Blood Cancer; 2013 Aug; 60(8):1375-81. PubMed ID: 23441093
[TBL] [Abstract][Full Text] [Related]
8. Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.
Vulsteke C; Pfeil AM; Maggen C; Schwenkglenks M; Pettengell R; Szucs TD; Lambrechts D; Dieudonné AS; Hatse S; Neven P; Paridaens R; Wildiers H
Breast Cancer Res Treat; 2015 Jul; 152(1):67-76. PubMed ID: 26017071
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms rs4673 and rs28714259 in predicting anthracycline-mediated cardiotoxicity in patients with breast cancer.
Gvaldin GD; Timoshkina TN; Vladimirova L; Svetitskaya SY; Vaschenko VL
Klin Onkol; 2021; 34(6):463-466. PubMed ID: 34911332
[TBL] [Abstract][Full Text] [Related]
10. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.
Blanco JG; Sun CL; Landier W; Chen L; Esparza-Duran D; Leisenring W; Mays A; Friedman DL; Ginsberg JP; Hudson MM; Neglia JP; Oeffinger KC; Ritchey AK; Villaluna D; Relling MV; Bhatia S
J Clin Oncol; 2012 May; 30(13):1415-21. PubMed ID: 22124095
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.
Blanco JG; Leisenring WM; Gonzalez-Covarrubias VM; Kawashima TI; Davies SM; Relling MV; Robison LL; Sklar CA; Stovall M; Bhatia S
Cancer; 2008 Jun; 112(12):2789-95. PubMed ID: 18457324
[TBL] [Abstract][Full Text] [Related]
12. Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients.
Ruiz-Pinto S; Pita G; Martín M; Alonso-Gordoa T; Barnes DR; Alonso MR; Herraez B; García-Miguel P; Alonso J; Pérez-Martínez A; Cartón AJ; Gutiérrez-Larraya F; García-Sáenz JA; Benítez J; Easton DF; Patiño-García A; González-Neira A
Breast Cancer Res Treat; 2018 Jan; 167(1):249-256. PubMed ID: 28913729
[TBL] [Abstract][Full Text] [Related]
13. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity.
Wojnowski L; Kulle B; Schirmer M; Schlüter G; Schmidt A; Rosenberger A; Vonhof S; Bickeböller H; Toliat MR; Suk EK; Tzvetkov M; Kruger A; Seifert S; Kloess M; Hahn H; Loeffler M; Nürnberg P; Pfreundschuh M; Trümper L; Brockmöller J; Hasenfuss G
Circulation; 2005 Dec; 112(24):3754-62. PubMed ID: 16330681
[TBL] [Abstract][Full Text] [Related]
14. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children.
Visscher H; Rassekh SR; Sandor GS; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Rogers PC; Rieder MJ; Carleton BC; Hayden MR; Ross CJ;
Pharmacogenomics; 2015; 16(10):1065-76. PubMed ID: 26230641
[TBL] [Abstract][Full Text] [Related]
15. The genetic underpinnings of anthracycline-induced cardiomyopathy predisposition.
Berkman AM; Hildebrandt MAT; Landstrom AP
Clin Genet; 2021 Aug; 100(2):132-143. PubMed ID: 33871046
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide association study of genetic variants related to anthracycline-induced cardiotoxicity in early breast cancer.
Park B; Sim SH; Lee KS; Kim HJ; Park IH
Cancer Sci; 2020 Jul; 111(7):2579-2587. PubMed ID: 32378780
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomic study of anthracycline-induced cardiotoxicity in Mexican pediatric patients.
Vargas-Neri JL; Carleton B; Ross CJ; Medeiros M; Castañeda-Hernández G; Clark P
Pharmacogenomics; 2022 Apr; 23(5):291-301. PubMed ID: 35147047
[No Abstract] [Full Text] [Related]
18. Association between genetic variants of transmembrane transporters and susceptibility to anthracycline-induced cardiotoxicity: Current understanding and existing evidence.
Ni MM; Yang JF; Miao J; Xu J
Clin Genet; 2024 Feb; 105(2):115-129. PubMed ID: 37961936
[TBL] [Abstract][Full Text] [Related]
19. CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin.
Lang JK; Karthikeyan B; Quiñones-Lombraña A; Blair RH; Early AP; Levine EG; Sharma UC; Blanco JG; O'Connor T
Cardiooncology; 2021 May; 7(1):17. PubMed ID: 33975650
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic testing to guide therapeutic decision-making and improve outcomes for children undergoing anthracycline-based chemotherapy.
Loucks CM; Yan K; Tanoshima R; Ross CJD; Rassekh SR; Carleton BC
Basic Clin Pharmacol Toxicol; 2022 Jan; 130 Suppl 1():95-99. PubMed ID: 33900042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
